Pharmacokinetics of DOLUTEGRAVIR once daily and ELVITEGRAVIR/COBICISTAT once daily over 10 days following drug intake cessation in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2016
At a glance
- Drugs Cobicistat (Primary) ; Dolutegravir (Primary) ; Elvitegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 12 Aug 2016 Status changed from active, no longer recruiting to completed.
- 17 Dec 2015 Results published in the Journal of Antimicrobial Chemotherapy
- 19 Feb 2015 Accrual to date is 112%, according to UK Clinical Trials Register.